Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review

Mirmosayyeb, Omid; Moases Ghaffary, Elham; Mazdak, Mahsa; Bagheri, Zahra; Bagherieh, Sara; Shaygannejad, Vahid

doi:https://doi.org/10.1155/2022/5009450

Canadian Journal of Infectious Diseases and Medical Microbiology

On this page

Abstract Introduction Methods Discussion Conclusion Data Availability Conflicts of Interest Authors’ Contributions Supplementary Materials References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 5009450 | https://doi.org/10.1155/2022/5009450

Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review

Omid Mirmosayyeb,^1,2Elham Moases Ghaffary,²Mahsa Mazdak,²Zahra Bagheri,²Sara Bagherieh,²and Vahid Shaygannejad^1,2

Academic Editor: Sanket Kaushik

Received21 Jul 2022

Revised07 Aug 2022

Accepted25 Aug 2022

Published17 Sept 2022

Abstract

Background. Myasthenia gravis (MG) is a neuromuscular, autoimmune disease that causes weakness by impairing neuromuscular transmission. According to reports, vaccines can lead to autoimmunity in different ways, and COVID-19 vaccines are suggested to trigger MG. We conducted this systematic review to assess MG patients after the COVID-19 vaccination. Methods. We collected 231 studies from four databases from inception to 26 March 2022. Results. 4 case studies were selected from 231 research studies, and data were extracted based on inclusion criteria. In all cases, MG was reported following COVID-19 vaccination. Symptoms such as muscle weakness, numbness, and ptosis were common. The MG was confirmed through RNST, MRC, NCS, and AchR-binding antibody titer tests. Conclusion. Although all cases of MG were diagnosed following appropriate tests, the sample size was small; therefore, further investigation is required to demonstrate the possible association between MG and COVID-19 vaccination.

1. Introduction

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that bind to neuromuscular junction (NMJ) components, disrupting normal function and reducing neuromuscular acetylcholine (ACh) transmission [1–3]. MG, which is characterized by the fatiguability of skeletal muscles and weakness of ocular, bulbar, respiratory, and axial muscles, typically affects ocular muscles at the beginning, resulting in diplopia and intermittent ptosis [4–6]. MG disease is associated with abnormal thymus, defective immune regulation, inflammation, and chronic cell activation [7]. Acetylcholinesterase inhibitors, immunosuppressant agents, steroids, and thymectomies are usually used to treat MG [3].

Viruses from the Coronaviridae family (severe acute respiratory syndrome coronavirus (SARS-CoV)) and Middle East respiratory syndrome coronavirus (MERS-CoV) are human respiratory pathogens. As a result of a new strain of SARS-CoV named SARS-COV-2, a global pandemic ensued in 2019. The patients suffered from mild symptoms such as fatigue, fever, and dry cough. Severe cases can experience acute respiratory distress syndrome (ARDS), cardiac and renal failure, and eventually death [8]. Several instances of COVID-19 infection have resulted in some complications in patients.

Due to the spread of SARS-CoV-2 among countries, global communities have responded to the urgent need for safe and effective COVID-19 vaccines with unprecedented speed and action [9]. There have been several SARS-CoV-2 vaccines developed and available around the world, including mRNA (i.e., Pfizer-BioNTech [BNT162b2] and Moderna [mRNA-1273]), viral vector (i.e., Johnson and Johnson’s Janssen [Ad26.COV2-S] and Oxford-AstraZeneca [ChAdOx1 nCoV-19]), and inactivated vaccines (Covaxin, CoronaVac, and Sinopharm), since December 2020. These vaccines have shown high efficacy and safety in protecting against SARS-CoV-2 infection [10, 11].

The common adverse events of the vaccine were redness, swelling, body pain, fatigue, headache, and fever [12, 13]. COVID-19 vaccine can rarely affect the central nervous system (CNS) and peripheral nervous system (PNS) and has been associated with neurological manifestations including stroke, Guillain-Barré syndrome (GBS), Bell’s palsy, autoimmune diseases (AID), cerebral venous sinus thrombosis (CVST), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), myalgia and arthralgia, and acute demyelinating polyneuropathy [14–16].

Although COVID-19 vaccines generate broad immunity against the infection and are the best and safest method for controlling the pandemic, a few cases and reports have shown onset MG associated with the COVID-19 vaccine. It is crucial to recognize less common symptoms related to COVID-19 vaccine-associated MG, including dysphagia and dysarthria and pay attention to the timing of vaccination. MG can be worsened and triggered by infection; however, no specific association with viruses or pathogens has been demonstrated. The underlying pathogenesis of MG is unclear but it is speculated that immune response changes following vaccination could generate antibodies against AChRs [14, 17–19].

The purpose of this systematic review was to collect all published cases of MG after receiving the COVID-19 vaccine.

2. Methods

2.1. Literature Study

At first, we systematically searched five databases, including Pubmed (Medline), Embase, Scopus, Web of Science, and Google Scholar, with the MeSH terms including “myasthenia gravis” and “COVID-19 Vaccines” (see the supplementary file) for identifying all studies from inception to 26 March 2022. In addition, all syntaxes were customized for each database.

2.2. Inclusion and Exclusion Criteria

All case report/series studies which included MG cases following the COVID-19 vaccine were included in the inclusion criteria. The exclusion criteria were as follows: articles written in any language other than English, review articles, animal studies, hypotheses, In vitro studies, as well as patients with MG who got vaccines and whose symptoms became worse after vaccination.

2.3. Study Selection

First, two researchers (ZB and MM) reviewed the related articles separately and selected desired studies afterward. Any differences in view between included and excluded studies were resolved by a senior reviewer (SV) comment.

2.4. Data Extraction

Two authors (ZB and MM) performed the extraction of data independently according to qualified information, including demographic data, comorbidities, name of the vaccine, time interval/dose, vaccine side effects, MG first signs and symptoms, physical examination findings, laboratory finding, electromyography (EMG) findings, radiologic findings, acute treatment, main treatment, and outcome(Table 1).

2.5. Quality Assessment

A systematic review evaluation tool, Joanna Brigs Institute (JBI), was used to assess the quality and risk of bias of each study [20]. Two researchers (MM and ZB) evaluated all studies, and the senior researcher (OM) resolved any disagreement. 4 options for evaluation were available “Yes,” “No,” “Unclear,” and “Not applicable.” Moreover, “Yes” responses were summarized from 0 to 8. Articles with a score lower than 4 are considered low quality, and those with a score higher than 4 are considered high quality (Tables 2 and 3).

3. Result

Using the PRISMA flowchart (Figure 1), studies were selected based on exclusion and inclusion criteria. At first, 229 articles were identified from 4 databases, then 38 records were removed before screening based on their duplication. 191 records were screened, and 187 were excluded based on their irrelevancy. Full-text articles were collected, and 4 articles were used in our study. Table 1 provides demographic information for 5 patients. 4 (75%) patients were male, the mean (SD) of their age was 66.6 (19.2), most of them got the BNT162b2 vaccine, and the main treatments of patients were pyridostigmine and prednisone. Finally, available data demonstrated that one patient was intubated while 4 recovered.

4. Discussion

Vaccines have profoundly affected human health and longevity, with statistics showing around nine million lives being saved each year by vaccination. Smallpox has been eradicated from the planet thanks to vaccination [21]. Vaccines are intended to make antibodies against pathogens, or trigger the immune system to deal with them more effectively. Even though modern vaccines are made on different platforms (whole germ, viral vector, nucleic acid-based, subunit, and nanoparticle-based vaccines), they all have components associated with some neurological damage and autoimmune side effects [22, 23]. We systematically review the existing publications on cases of MG following SARS-CoV-2 vaccination.

4.1. SARS-CoV-2 Vaccines

The COVID-19 pandemic has affected human lives in various social, economic, and health aspects. These issues include lockdowns, economic slowdowns, limited freedoms, being infected, and losing loved ones [24]. Vaccination seems to be the most efficacious intervention in combating this pandemic [25]. At the time of writing, there are 149 SARS-COV-2 vaccines in clinical development and 195 vaccines in preclinical development, according to the WHO database [26]. In December 2020, the first-ever vaccine for combating SARS-COV-2 infection was approved as an mRNA-based vaccine, BNT162b2 [27]. Up to now, available vaccines include mRNA vaccines (CVnCoV, mRNA-1273, and BNT16b2), inactivated vaccines (Wuhan Sinopharm, CoronaVac, NVX-COV2373, BBIBP-CorV, Covaxin, KoviVac, QazVac, and COVIran Barekat), viral vector vaccines (Sputnik V Light, Sputnik V, AZD1222, Ad26.COV2.S, and Ad5-nCoV), and protein-based vaccines (Abdala, ZF200, and EpiVacCorona) [11].

4.2. SARS-CoV-2 Vaccine-Induced MG

Even though COVID-19 vaccines were administered to protect against SARS-COV-2 infection not long ago, a variety of adverse effects have been reported. Molecular mimicry between SARS-CoV-2 molecules and human antigens can cause AID in vaccine receivers [28]. Vojdani and Kharrazian proved the cross-reactivity of 21 human tissue antigens with the SARS-CoV-2 antibodies, which can be responsible for the fact that COVID-19 infections and SARS-COV-2 mRNA vaccines trigger autoimmunity against gastrointestinal, cardiovascular, nervous systems, and connective tissues [29]. It may also result in aberrant activation of acquired and innate immunity when mRNA vaccines trigger a cascade of immune reactions [30]. In addition, certain adjuvants are likely to cause self auto-reactive T cells differentiation, which will damage the host tissues [31]. The adjuvants are molecules that induce innate immunity by activating the pattern recognition receptors (PRRs). Therefore, vaccines commonly contain them to grow immunity against antigens [32, 33]. SARS-CoV-2 adjuvanticity of vaccines works as toll-like receptors (TLR)-7/8, or TLR-9 agonist and is novel compared to previous vaccines. This can be a new pathogenic mechanism causing immune-mediated diseases in people [34, 35].

The findings of multiple studies suggest HPV vaccinations may cause MG either as an adverse event or incidentally without a relationship between them [36]. It has been hypothesized that an antibody that cross-reacts with autonomic ganglia, neurons, and cardiovascular proteins could be synthesized by the HPV vaccine epitope and that the production of the antibody could activate cytotoxic T cells by binding to acetylcholine receptors [36, 37]. The other number of factors, including hepatitis B virus (HBV) [38, 39], bacillus Calmette–Guerin (BCG) [40], and the influenza vaccines [41], led to MG.

Chavez and Pougnier reported an 82-year-old man with slurred speech symptoms two days after receiving his second dose of an mRNA-based COVID-19 vaccine. Due to the high titers of AchR-antibodies in his serum and his EMG test results, he was confirmed to develop MG following vaccination. Also, after two weeks of treatment, he was bothered by droopy eyelids [18]. Based on the very short time between vaccine injection and showing symptoms, bystander immunity can be the underlying explanation, in which a continuous immune response and inflammation allow autoantigens to be exposed and autoreactive T lymphocytes to be activated [42]. In contrast, Lee et al. reported a 33-year-old female with myalgia, generalized weakness, diplopia, and ptosis following the second dose of an mRNA-based COVID-19 vaccine, who developed thymic hyperplasia, as well as an absence of antibodies to AchR and muscle-specific tyrosine kinase (MuSK). Nevertheless, it is still hypothesized that alternations in immune response following vaccination may produce antibodies against AchR and this seronegative MG patient may have antibodies that cannot be detected by current assay methods [14].

Interestingly, Tagliaferri et al. reported an MG crisis following an mRNA-based vaccine in a patient diagnosed with MG 5 years prior. They acknowledged that the cytokine storm caused an MG flare in their patient, especially when he showed improvement after low-dose steroid therapy [3], which decreased lymphocyte proliferation, differentiation, and cytokine expression [43]. Moreover, an MG crisis caused the death of an 86-year-old patient after the vaccination [44]. Despite all these, the capacity of the SARS-COV-2 virus to cause neurological damage is way much more than COVID-19 vaccines [45–51].

As a strong explanation, it can be said that inflammatory responses in MG are stimulated and sustained by TLR signaling pathways activation [52–57]. On the other hand, activating adaptive immunity in response to vaccines is also controlled by TLRs pathways. These findings show that TLRs are involved in vaccine effectiveness and MG pathogenesis [58].

Moreover, a TLR3 agonist known as polyinosine-polycytidylic acid can cause changes in the thymus (which is supposed to be related to MG pathogenesis [59]) and flares MG symptoms through imitating virus double-stranded RNA (dsRNA), which is the replicative virus component [55]. Therefore, any COVID-19 vaccine that contains adjuvant or pathogen antigen molecule mimicking dsRNA can activate the TLR3 pathway and perhaps cause an autoimmune response against acetylcholine receptors [58].

We systematically evaluated all cases presenting MG patients following COVID-19 with different vaccines injection. Our systematic review is the first conducted in this field. We were constrained by some limitations, such as the small number of cases indicating that they are not representative of the population. More studies are needed to clarify the actual relationship between COVID-19 vaccines and MG in healthy individuals or MG flare in those who are susceptible.

5. Conclusion

While COVID-19 vaccines provide broad immunity against the infection and are among the most effective and safe methods of controlling this pandemic, the onset of MG has been associated with the vaccine in a small number of cases; nonetheless, given the small number of cases reported, it cannot be conceded that MG is necessarily a complication of the COVID-19 different vaccines, and more data and cases are needed for the conclusion.

Data Availability

The datasets analyzed during the current study are available upon request with no restriction.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All the authors listed in the article have participated actively in preparing the final version of this case report.

Supplementary Materials

Table S1. The customized syntaxes based on each database. . (Supplementary Materials)

References

C. A. Payet, A. You, O.-M. Fayet, N. Dragin, S. Berrih-Aknin, and R. Le Panse, “Myasthenia gravis: an acquired interferonopathy?” Cells, vol. 11, no. 7, p. 1218, 2022.
View at: Publisher Site | Google Scholar
M. N. Meriggioli and D. B. Sanders, “Muscle autoantibodies in myasthenia gravis: beyond diagnosis?” Expert Review of Clinical Immunology, vol. 8, no. 5, pp. 427–438, 2012.
View at: Publisher Site | Google Scholar
A. R. Tagliaferri, S. Narvaneni, M. H. Azzam, and W. Grist, “A case of COVID-19 vaccine causing a myasthenia gravis crisis,” CUREUS, vol. 13, Article ID e15581, 6 pages, 2021.
View at: Publisher Site | Google Scholar
M. K. Hehir and N. J. Silvestri, “Generalized myasthenia gravis,” Neurologic Clinics, vol. 36, no. 2, pp. 253–260, 2018.
View at: Publisher Site | Google Scholar
K. Lazaridis and S. J. Tzartos, “Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics,” Frontiers in Immunology, vol. 11, p. 212, 2020.
View at: Publisher Site | Google Scholar
N. Silvestri and G. Wolfe, “Myasthenia gravis,” Seminars in Neurology, vol. 32, no. 3, pp. 215–226, 2012.
View at: Publisher Site | Google Scholar
J.-T. Vilquin, A. C. Bayer, R. Le Panse, and S. Berrih-Aknin, “The muscle is not a passive target in myasthenia gravis,” Frontiers in Neurology, vol. 10, p. 1343, 2019.
View at: Publisher Site | Google Scholar
H. A. Rothan and S. N. Byrareddy, “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak,” Journal of Autoimmunity, vol. 109, Article ID 102433, 2020.
View at: Publisher Site | Google Scholar
K. L. Flanagan, C. R. MacIntyre, P. B. McIntyre, and M. R. Nelson, “SARS-CoV-2 vaccines: where are we now?” The Journal of Allergy and Clinical Immunology: In Practice, vol. 9, no. 10, pp. 3535–3543, 2021.
View at: Publisher Site | Google Scholar
F. B. S. Briggs, F. J. Mateen, H. Schmidt et al., “COVID-19 vaccination reactogenicity in persons with multiple sclerosis,” Neurology-Neuroimmunology Neuroinflammation, vol. 9, no. 1, Article ID e1104, 2022.
View at: Publisher Site | Google Scholar
T. Fiolet, Y. Kherabi, C.-J. MacDonald, J. Ghosn, and N. Peiffer-Smadja, “Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review,” Clinical Microbiology and Infection, vol. 28, no. 2, pp. 202–221, 2022.
View at: Publisher Site | Google Scholar
R. J. Kaur, S. Dutta, P. Bhardwaj et al., “Adverse events reported from COVID-19 vaccine trials: a systematic review,” Indian Journal of Clinical Biochemistry, vol. 36, no. 4, pp. 427–439, 2021.
View at: Publisher Site | Google Scholar
Q. A. Al Khames Aga, W. H. Alkhaffaf, T. H. Hatem et al., “Safety of COVID-19 vaccines,” Journal of Medical Virology, vol. 93, no. 12, pp. 6588–6594, 2021.
View at: Publisher Site | Google Scholar
M. A. Lee, C. Lee, J. H. Park, and J. H. Lee, “Early-onset myasthenia gravis following COVID-19 vaccination,” Journal of Korean Medical Science, vol. 37, no. 10, p. e50, 2022.
View at: Publisher Site | Google Scholar
L. D. Kaulen, S. Doubrovinskaia, C. Mooshage et al., “Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series,” European Journal of Neurology, vol. 29, no. 2, pp. 555–563, 2022.
View at: Publisher Site | Google Scholar
R. K. Garg and V. K. Paliwal, “Spectrum of neurological complications following COVID-19 vaccination,” Neurological Sciences, vol. 43, no. 1, pp. 3–40, 2022.
View at: Publisher Site | Google Scholar
A. Watad, G. De Marco, H. Mahajna et al., “Immune-mediated disease flares or new-onset disease in 27 subjects following mrna/dna sars-cov-2 vaccination,” Vaccines, vol. 9, no. 5, p. 435, 2021.
View at: Publisher Site | Google Scholar
A. Chavez and C. Pougnier, “A case of COVID-19 vaccine associated new diagnosis myasthenia gravis,” Journal of Primary Care and Community Health, vol. 12, Article ID 215013272110519, 2021.
View at: Publisher Site | Google Scholar
G. Galassi, V. Rispoli, E. Iori, A. Ariatti, and A. Marchioni, “Coincidental onset of ocular myasthenia gravis following ChAdOx1 n-CoV-19 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),” The Israel Medical Association Journal: IMAJ, vol. 24, no. 1, 2022.
View at: Google Scholar
C. Lockwood, Z. Munn, K. Porritt, and Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation, “International Journal of Evidence-Based Healthcare,” vol. 13, no. 3, pp. 179–187, 2015.
View at: Google Scholar
U. N. C. F. Unicef, Vaccines Bring Control., Diseases Under, Unicef, New York, N.Y, USA, 2019.
L. Lu, W. Xiong, J. Mu et al., “The potential neurological effect of the COVID-19 vaccines: a review,” Acta Neurologica Scandinavica, vol. 144, no. 1, pp. 3–12, 2021.
View at: Publisher Site | Google Scholar
I. I. Ismail and S. Salama, “A systematic review of cases of CNS demyelination following COVID-19 vaccination,” Journal of Neuroimmunology, vol. 362, Article ID 577765, 2022.
View at: Publisher Site | Google Scholar
N. Haug, L. Geyrhofer, A. Londei et al., “Ranking the effectiveness of worldwide COVID-19 government interventions,” Nature Human Behaviour, vol. 4, no. 12, pp. 1303–1312, 2020.
View at: Publisher Site | Google Scholar
S. Saxena, H. Skirrow, and H. Bedford, “Routine vaccination during COVID-19 pandemic response,” BMJ, vol. 369, Article ID m2392, 2020.
View at: Publisher Site | Google Scholar
WHO - R&D Blue Print, COVID-19 Vaccine Tracker and Landscape - 28 January 2022, WHO R&D Blue Print, Geneva, Switzerland, 2022.
E. E. Ooi, A. Dhar, R. Petruschke, C. Locht, P. Buchy, and J. G. H. Low, “Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination,” Npj Vaccines, vol. 7, no. 1, p. 31, 2022.
View at: Publisher Site | Google Scholar
D. Kanduc and Y. Shoenfeld, “Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine,” Immunologic Research, vol. 68, no. 5, pp. 310–313, 2020.
View at: Publisher Site | Google Scholar
A. Vojdani and D. Kharrazian, “Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases,” Clinical Immunology, vol. 217, Article ID 108480, 2020.
View at: Publisher Site | Google Scholar
R. Talotta, “Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to ‘potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases,” Clinical Immunology, vol. 224, Article ID 108665, 2021.
View at: Publisher Site | Google Scholar
S. Goriely and M. Goldman, “From tolerance to autoimmunity: is there a risk in early life vaccination?” Journal of Comparative Pathology, vol. 137, no. SUPPL. 1, pp. 57–61, 2007.
View at: Publisher Site | Google Scholar
N. L. Bragazzi, A. Watad, K. Sharif et al., “Advances in our understanding of immunization and vaccines for patients with systemic lupus erythematosus,” Expert Review of Clinical Immunology, vol. 13, no. 10, pp. 939–949, 2017.
View at: Publisher Site | Google Scholar
É. Toussirot and M. Bereau, “Vaccination and induction of autoimmune diseases,” Inflammation & Allergy-Drug Targets, vol. 14, no. 2, pp. 94–98, 2016.
View at: Publisher Site | Google Scholar
M. Tatematsu, K. Funami, T. Seya, and M. Matsumoto, “Extracellular RNA sensing by pattern recognition receptors,” Journal of Innate Immunity, vol. 10, no. 5–6, pp. 398–406, 2018.
View at: Publisher Site | Google Scholar
J. R. Teijaro and D. L. Farber, “COVID-19 vaccines: modes of immune activation and future challenges,” Nature Reviews Immunology, vol. 21, no. 4, pp. 195–197, 2021.
View at: Publisher Site | Google Scholar
J. Y. Chung, S. J. Lee, B.-S. Shin, and H. G. Kang, “Myasthenia gravis following human papillomavirus vaccination: a case report,” BMC Neurology, vol. 18, no. 1, pp. 222–224, 2018.
View at: Publisher Site | Google Scholar
L. A. Pinto, P. E. Castle, R. B. Roden et al., “HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood,” Vaccine, vol. 23, no. 27, pp. 3555–3564, 2005.
View at: Publisher Site | Google Scholar
B. Louzir, S. Othmani, R. Battikh et al., “Myasthenia after hepatitis B vaccination,” Therapie, vol. 58, no. 4, pp. 378-379, 2003.
View at: Publisher Site | Google Scholar
J.-P. Stübgen, “Neuromuscular disorders associated with Hepatitis B vaccination,” Journal of the Neurological Sciences, vol. 292, no. 1–2, pp. 1–4, 2010.
View at: Publisher Site | Google Scholar
T. Takizawa, M. Kojima, S. Suzuki et al., “New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: a case report and literature review,” Medicine (Baltimore), vol. 96, Article ID e8757, 46 pages, 2017.
View at: Publisher Site | Google Scholar
F. Wang, T. Xiang, L. He, and J. Wang, “Laryngeal myasthenia gravis following influenza vaccination: a case report and literature review,” Human Vaccines and Immunotherapeutics, vol. 17, no. 12, pp. 5529–5531, 2021.
View at: Publisher Site | Google Scholar
D. C. Wraith, M. Goldman, and P. H. Lambert, “Vaccination and autoimmune disease: what is the evidence?” Lancet, vol. 362, no. 9396, pp. 1659–1666, 2003.
View at: Publisher Site | Google Scholar
K. Kragballe, “Topical corticosteroids: mechanisms of action,” Acta Dermato-Venereologica, Supplementum, vol. 69, no. 151, pp. 7–10, 1989.
View at: Google Scholar
M. Flores, T. Kewan, K. Mushtaq et al., “Characteristics and outcomes of adverse events after COVID-19 vaccination,” Journal of the American College of Emergency Physicians open, vol. 2, Article ID e12565, 2021.
View at: Publisher Site | Google Scholar
M. A. Ellul, L. Benjamin, B. Singh et al., “Neurological associations of COVID-19,” The Lancet Neurology, vol. 19, no. 9, pp. 767–783, 2020.
View at: Publisher Site | Google Scholar
E. J. Needham, S. H.-Y. Chou, A. J. Coles, and D. K. Menon, “Neurological implications of COVID-19 infections,” Neurocritical Care, vol. 32, no. 3, pp. 667–671, 2020.
View at: Publisher Site | Google Scholar
A. Filatov, P. Sharma, F. Hindi, and P. S. Espinosa, “Neurological complications of coronavirus disease (COVID-19): encephalopathy,” Cureus, vol. 12, no. 3, Article ID e7352, 2020.
View at: Publisher Site | Google Scholar
A. Jarrahi, M. Ahluwalia, H. Khodadadi et al., “Neurological consequences of COVID-19: what have we learned and where do we go from here?” Journal of Neuroinflammation, vol. 17, no. 1, p. 286, 2020.
View at: Publisher Site | Google Scholar
E. Beghi, V. Feigin, V. Caso, P. Santalucia, and G. Logroscino, “COVID-19 infection and neurological complications: present findings and future predictions,” Neuroepidemiology, vol. 54, no. 5, pp. 364–369, 2020.
View at: Publisher Site | Google Scholar
I. Siow, K. S. Lee, J. J. Y. Zhang, S. E. Saffari, A. Ng, and B. Young, “Stroke as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes and predictors,” Journal of Stroke and Cerebrovascular Diseases, vol. 30, no. 3, Article ID 105549, 2021.
View at: Publisher Site | Google Scholar
M. E. V. Collantes, A. I. Espiritu, M. C. C. Sy, V. M. M. Anlacan, and R. D. G. Jamora, “Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis,” The Canadian Journal of Neurological Sciences, vol. 48, no. 1, pp. 66–76, 2021.
View at: Publisher Site | Google Scholar
Y. Z. Wang, M. Yan, F. F. Tian et al., “Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis,” Inflammation, vol. 36, no. 1, pp. 121–130, 2013.
View at: Publisher Site | Google Scholar
P. Bernasconi, M. Barberis, F. Baggi et al., “Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution,” The American Journal of Pathology, vol. 167, no. 1, pp. 129–139, 2005.
View at: Publisher Site | Google Scholar
M. Robinet, S. Maillard, M. A. Cron, S. Berrih-Aknin, and R. Le Panse, “Review on toll-like receptor activation in myasthenia gravis: application to the development of new experimental models,” Clinical Reviews in Allergy & Immunology, vol. 52, no. 1, pp. 133–147, 2017.
View at: Publisher Site | Google Scholar
P. Cufi, N. Dragin, J. M. Weiss et al., “Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis,” Annals of Neurology, vol. 73, no. 2, pp. 281–293, 2013.
View at: Publisher Site | Google Scholar
C. Cordiglieri, R. Marolda, S. Franzi et al., “Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity,” Journal of Autoimmunity, vol. 52, pp. 74–89, 2014.
View at: Publisher Site | Google Scholar
P. Cavalcante, B. Galbardi, S. Franzi et al., “Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein–Barr virus infection,” Immunobiology, vol. 221, no. 4, pp. 516–527, 2016.
View at: Publisher Site | Google Scholar
Q. Zhou, R. Zhou, H. Yang, and H. Yang, “To be or not to be vaccinated: that is a question in myasthenia gravis,” Frontiers in Immunology, vol. 12, Article ID 733418, 2021.
View at: Publisher Site | Google Scholar
K. Utsugisawa and Y. Nagane, “[Thymic abnormalities in patients with myasthenia gravis],” Brain Nerve, vol. 63, no. 7, pp. 685–694, 2011.
View at: Google Scholar

Copyright

Copyright © 2022 Omid Mirmosayyeb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

766

Downloads

674

Citations